📣 VC round data is live. Check it out!

Lucid Diagnostics Valuation Multiples

Discover Lucid Diagnostics' revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Medinice, Sanara MedTech, Asterasys, Ilex Medical and more.

Lucid Diagnostics Overview

About Lucid Diagnostics

Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.


Founded

2018

HQ

United States

Employees

72

Financials (LTM)

Revenue: $6M
EBITDA: ($52M)

EV

$207M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Lucid Diagnostics Financials

Lucid Diagnostics reported last 12-month revenue of $6M and negative EBITDA of ($52M).

In the same LTM period, Lucid Diagnostics generated ($728K) in gross profit, ($52M) in EBITDA losses, and had net loss of ($55M).

Revenue (LTM)


Lucid Diagnostics P&L

In the most recent fiscal year, Lucid Diagnostics reported revenue of $5M and EBITDA of ($57M).

Lucid Diagnostics is unprofitable as of last fiscal year, with gross margin of (42%), EBITDA margin of (1203%), and net margin of (1233%).

See analyst estimates for Lucid Diagnostics
LTMLast FY202320242025202620272028
Revenue$6M$5M$2M$4M$5M
Gross Profit($728K)($2M)($4M)($3M)($2M)
Gross Margin(12%)(42%)(146%)(63%)(42%)
EBITDA($52M)($57M)($50M)($44M)($57M)
EBITDA Margin(893%)(1203%)(2049%)(1020%)(1214%)
EBIT Margin(818%)(1030%)(1997%)(1060%)(1055%)
Net Profit($55M)($58M)($53M)($46M)($58M)
Net Margin(949%)(1233%)(2169%)(1048%)(1233%)

Financial data powered by Morningstar, Inc.

Lucid Diagnostics Stock Performance

Lucid Diagnostics has current market cap of $198M, and enterprise value of $207M.

Market Cap Evolution


Lucid Diagnostics' stock price is $1.04.

Lucid Diagnostics share price increased by 0.5% in the last 30 days, and decreased by 14.9% in the last year.

Lucid Diagnostics has an EPS (earnings per share) of $-0.30.

See more trading valuation data for Lucid Diagnostics
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$207M$198M1.0%0.5%-9.6%-14.9%$-0.30

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Lucid Diagnostics Valuation Multiples

Lucid Diagnostics trades at 35.6x EV/Revenue multiple, and (4.0x) EV/EBITDA.

See NTM and 2027E valuation multiples for Lucid Diagnostics

EV / Revenue (LTM)


Lucid Diagnostics Financial Valuation Multiples

As of June 3, 2026, Lucid Diagnostics has market cap of $198M and EV of $207M.

Lucid Diagnostics has a P/E ratio of (3.6x).

LTMLast FY202320242025202620272028
EV/Revenue35.6x44.1x85.4x47.7x44.1x
EV/EBITDA(4.0x)(3.7x)(4.2x)(4.7x)(3.6x)
EV/EBIT(4.3x)(4.3x)(4.3x)(4.5x)(4.2x)
EV/Gross Profitn/m(105.6x)(58.4x)(75.4x)(105.6x)
P/E(3.6x)(3.4x)(3.8x)(4.4x)(3.4x)
EV/FCF-(4.4x)(6.3x)(4.6x)(4.4x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Lucid Diagnostics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Lucid Diagnostics Margins & Growth Rates

Lucid Diagnostics grew revenue by 57% but EBITDA decreased by 19% in the last fiscal year.

In the most recent fiscal year, Lucid Diagnostics reported gross margin of (42%), EBITDA margin of (1203%), and net margin of (1233%).

See estimated margins and future growth rates for Lucid Diagnostics

Lucid Diagnostics Margins

Last FY202420252026202720282029
Gross Margin(42%)(63%)(42%)14%
EBITDA Margin(1203%)(1020%)(1214%)(621%)
EBIT Margin(1030%)(1060%)(1055%)(633%)
Net Margin(1233%)(1048%)(1233%)(702%)
FCF Margin(992%)(1031%)(992%)-

Lucid Diagnostics Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth57%79%8%57%
Gross Profit Growth(151%)(22%)(29%)(151%)
EBITDA Growth(19%)(11%)29%(20%)
EBIT Growth(4%)(5%)8%(6%)
Net Profit Growth(11%)(14%)27%(11%)
FCF Growth-36%4%-

Data powered by FactSet, Inc. and Morningstar, Inc.

Lucid Diagnostics Operational KPIs

Lucid Diagnostics' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.7M for the same period.

Lucid Diagnostics' Rule of 40 is (565%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Lucid Diagnostics' Rule of X is (479%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Lucid Diagnostics
LTMLast FY202320242025202620272028
Rule of 40(774%)(565%)---
Bessemer Rule of X(596%)(479%)---
Revenue per Employee-$0.1M---
Opex per Employee-$0.7M---
S&M Expenses to Revenue317%376%676%379%376%
G&A Expenses to Revenue409%511%793%464%507%
R&D Expenses to Revenue97%121%299%138%121%
Opex to Revenue-1013%1851%996%1013%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Lucid Diagnostics Competitors

Lucid Diagnostics competitors include Medinice, Sanara MedTech, Asterasys, Ilex Medical, RxSight, TriSalus Life Sciences, Anika Therapeutics, Surgical Science, Pro-Dex and Huons Co.

Most Lucid Diagnostics public comparables operate across Medical Devices, Medical Imaging & Diagnostics, HealthTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Medinice--(111.9x)-
Sanara MedTech2.2x2.1x13.6x13.7x
Asterasys7.5x6.3x22.7x18.2x
Ilex Medical0.4x-3.3x-
RxSight(0.0x)(0.0x)0.1x0.0x
TriSalus Life Sciences4.0x3.7x(11.1x)(12.2x)
Anika Therapeutics1.6x1.5x33.0x24.0x
Surgical Science1.0x1.0x5.6x6.1x

This data is available for Pro users. Sign up to see all Lucid Diagnostics competitors and their valuation data.

Start Free Trial

Acquisitions by Lucid Diagnostics

Lucid Diagnostics has acquired 1 company to date.

Last acquisition by Lucid Diagnostics was on October 7th 2021. Lucid Diagnostics acquired CapNostics for $2M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Lucid Diagnostics

CapNostics
Description
CapNostics is a medical device company offering the EsoCheck device, an FDA 510(k)-cleared non-endoscopic tool for detecting esophageal cell abnormalities. The swallowable capsule retrieves cells for biomarker analysis targeting Barrett’s esophagus, esophageal cancer precursors, and H. pylori. CapNostics partners with genomic labs for sequencing-based diagnostics. Based in New York, it advances outpatient screening protocols.
HQ CountryUnited States
HQ City
Upper Black Eddy, PA
Deal Date7 Oct 2021
Valuation$2M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Lucid Diagnostics acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Lucid Diagnostics

When was Lucid Diagnostics founded?Lucid Diagnostics was founded in 2018.
Where is Lucid Diagnostics headquartered?Lucid Diagnostics is headquartered in United States.
How many employees does Lucid Diagnostics have?As of today, Lucid Diagnostics has over 72 employees.
Who is the CEO of Lucid Diagnostics?Lucid Diagnostics' CEO is Lishan Aklog.
Is Lucid Diagnostics publicly listed?Yes, Lucid Diagnostics is a public company listed on Nasdaq.
What is the stock symbol of Lucid Diagnostics?Lucid Diagnostics trades under LUCD ticker.
When did Lucid Diagnostics go public?Lucid Diagnostics went public in 2021.
Who are competitors of Lucid Diagnostics?Lucid Diagnostics main competitors include Medinice, Sanara MedTech, Asterasys, Ilex Medical, RxSight, TriSalus Life Sciences, Anika Therapeutics, Surgical Science, Pro-Dex, Huons Co.
What is the current market cap of Lucid Diagnostics?Lucid Diagnostics' current market cap is $198M.
What is the current revenue of Lucid Diagnostics?Lucid Diagnostics' last 12 months revenue is $6M.
What is the current revenue growth of Lucid Diagnostics?Lucid Diagnostics revenue growth (NTM/LTM) is 119%.
What is the current EV/Revenue multiple of Lucid Diagnostics?Current revenue multiple of Lucid Diagnostics is 35.6x.
Is Lucid Diagnostics profitable?No, Lucid Diagnostics is not profitable.
What is the current EBITDA of Lucid Diagnostics?Lucid Diagnostics has negative EBITDA and is not profitable.
What is Lucid Diagnostics' EBITDA margin?Lucid Diagnostics' last 12 months EBITDA margin is (893%).
What is the current EV/EBITDA multiple of Lucid Diagnostics?Current EBITDA multiple of Lucid Diagnostics is (4.0x).
How many companies Lucid Diagnostics has acquired to date?As of June 2026, Lucid Diagnostics has acquired 1 company.
What was the largest acquisition by Lucid Diagnostics?$2M acquisition of CapNostics on 7th October 2021 was the largest M&A Lucid Diagnostics has done to date.
What companies Lucid Diagnostics acquired?Lucid Diagnostics acquired CapNostics.
In how many companies Lucid Diagnostics has invested to date?Lucid Diagnostics hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Lucid Diagnostics

Lists including Lucid Diagnostics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial